#OP0241 FASTLANE phase 4 trial showed TOFA was superior to PBO in early active axSpA, achieving significantly higher ASDAS inactive disease rates at 16 weeks (26.4% vs 7.4%) on background of naproxen. MRI osteitis improvement numerically favoured TOFA. #EULAR2026 @RheumNow https://t.co/dGETjkmfrh